Biggest changeOther new pronouncements issued but not effective as of December 31, 2022 are not expected to have a material impact on the Company’s financial statements. 22 Results of Operations Comparison of the Years Ended December 31, 2022 and 2021 Year Ended December 31, 2022 2021 $ Change Revenues Product Revenue 694,286 607,783 86,503 Milestone and engineering 528,500 - 528,500 Total Revenues 1,222,786 607,783 615,003 Costs and Expenses Cost of Revenue 2,011,459 1,902,414 109,045 Research, development and manufacturing operations 5,975,921 4,140,319 1,835,602 Selling, general and administrative 4,736,562 3,297,982 1,438,580 Share-based compensation 5,478,734 - 5,478,734 Depreciation and amortization 75,645 57,314 18,331 Total Costs and Expenses 18,278,321 9,398,029 8,880,292 Loss From Operations (17,055,535 ) (8,790,246 ) (8,265,289 ) Other Income/(Expense) Other Income/(Expense), net 33,100 (169,423 ) 202,523 Interest Expense (2,704,909 ) (1,088,327 ) (1,616,582 ) Change in fair value of derivatives and gain on extinguishment of liabilities - 4,047,993 (4,047,993 ) Total Other Income/(Expense) (2,671,809 ) 2,790,243 (5,462,052 ) Income/(Loss) on Equity Method Investment (27,361 ) - (27,361 ) Net Income/(Loss) (19,754,705 ) (6,000,003 ) (13,754,702 ) Revenues.
Biggest changeSee Note 2 for additional information. 20 Results of Operations Comparison of the Years Ended December 31, 2023 and 2022 Year Ended December 31, 2023 2022 $ Change Revenues Product Revenue 397,886 694,286 (296,400 ) Milestone and engineering 60,374 528,500 (468,126 ) Total Revenues 458,260 1,222,786 (764,526 ) Costs and Expenses Cost of Revenue 1,892,341 2,011,459 (119,118 ) Research, development and manufacturing operations 3,222,283 5,975,921 (2,753,638 ) Selling, general and administrative 5,364,523 4,736,562 627,961 Share-based compensation 2,243,445 5,478,734 (3,235,289 ) Depreciation and amortization 95,238 75,645 19,593 Impairment loss 3,283,715 - 3,283,715 Total Costs and Expenses 16,101,545 18,278,321 (2,176,776 ) Loss From Operations (15,643,285 ) (17,055,535 ) 1,412,250 Other Income/(Expense) Other Income/(Expense), net 747,739 33,100 714,639 Interest Expense (2,174,118 ) (2,704,909 ) 530,791 Total Other Income/(Expense) (1,426,379 ) (2,671,809 ) 1,245,430 Income/(Loss) on Equity Method Investment (232 ) (27,361 ) 27,129 Net Income/(Loss) (17,069,896 ) (19,754,705 ) 2,684,809 Revenues.
The value of the portion of the award that is ultimately expected to vest, net of estimated forfeitures, is recognized as expense on a straight-line basis, over the 21 requisite service period in the Company’s Statements of Operations. Share-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures.
The value of the portion of the award that is ultimately expected to vest, net of estimated forfeitures, is recognized as expense on a straight-line basis, over the requisite service period in the Company’s Statements of Operations. Share-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures.
Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company estimates the fair value of its restricted stock awards as its stock price on the grant date.
Forfeitures are estimated at the time of grant and revised, as necessary, 19 in subsequent periods if actual forfeitures differ from those estimates. The Company estimates the fair value of its restricted stock awards as its stock price on the grant date.
Actual results may differ from these 20 estimates under different assumptions or conditions. We have identified the policies below as critical to our business operations and to the understanding of our financial results: Significant Accounting Policies Inventories: All inventories are stated at the lower of cost or net realizable value, with cost determined using the weighted average method.
Actual results may differ from these estimates under different assumptions or conditions. We have identified the policies below as critical to our business operations and to the understanding of our financial results: 18 Significant Accounting Policies Inventories: All inventories are stated at the lower of cost or net realizable value, with cost determined using the weighted average method.
Convertible Debt: The Company evaluates its convertible debt instruments to determine if there is an embedded derivative or other feature that requires bifurcation from the host contract. Please refer to Note 12 for further discussion on each convertible debt.
Convertible Debt: The Company evaluates its convertible debt instruments to determine if there is an embedded derivative or other feature that requires bifurcation from the host contract. Please refer to Note 10 for further discussion on each convertible debt.
Significant Trends, Uncertainties and Challenges We believe the significant trends, uncertainties and challenges that directly or indirectly affect our financial performance and results of operations include: • Our ability to generate customer acceptance of and demand for our products; • Successful ramping up of commercial production on the equipment installed; • The substantial doubt about our ability to continue as a going concern due to our history of operating losses; • Our products are successfully and timely certified for use in our target markets; • Successful operating of production tools to achieve the efficiencies, throughput and yield necessary to reach our cost targets; • The products we design are saleable at a price sufficient to generate profits; • Our ability to raise sufficient capital to enable us to reach a level of sales sufficient to achieve profitability on terms favorable to us; • Effective management of the planned ramp up of our domestic and international operations; • Our ability to successfully develop and maintain strategic relationships with key partners, including OEMs, system integrators, and distributors, who deal directly with end users in our target markets; • Our ability to maintain the listing of our common stock on the Nasdaq Capital Market; • Our ability to maintain effective internal controls over financial reporting; • Our ability to achieve projected operational performance and cost metrics; • Our ability to enter into commercially viable licensing, joint venture, or other commercial arrangements; • Availability of raw materials; and • COVID-19 and the uncertainty around the continued duration and effect of the worldwide pandemic.
Significant Trends, Uncertainties and Challenges We believe the significant trends, uncertainties and challenges that directly or indirectly affect our financial performance and results of operations include: • Our ability to generate customer acceptance of and demand for our products; • Successful ramping up of commercial production on the equipment installed; • The substantial doubt about our ability to continue as a going concern due to our history of operating losses; • Our products are successfully and timely certified for use in our target markets; • Successful operating of production tools to achieve the efficiencies, throughput and yield necessary to reach our cost targets; • The products we design are saleable at a price sufficient to generate profits; • Our ability to raise sufficient capital to enable us to reach a level of sales sufficient to achieve profitability on terms favorable to us; • Effective management of the planned ramp up of our domestic and international operations; • Our ability to successfully develop and maintain strategic relationships with key partners, including OEMs, system integrators, and distributors, who deal directly with end users in our target markets; • Our ability to maintain the listing of our common stock on the Nasdaq Capital Market; • Our ability to maintain effective internal controls over financial reporting; • Our ability to achieve projected operational performance and cost metrics; • Our ability to enter into commercially viable licensing, joint venture, or other commercial arrangements; and • Availability of raw materials.
An undiscounted cash flow analysis is calculated to determine if an impairment exists. If an impairment is determined to exist, any related loss is calculated using the difference between the fair value and the carrying value of the assets.
An undiscounted cash flow analysis is estimated to determine if an impairment exists. If an impairment is determined to exist, any related loss is calculated using the difference between the fair value (estimated using the undiscounted cash flows) and the carrying value of the assets.
Off Balance Sheet Transactions As of December 31, 2022, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.
Off Balance Sheet Transactions As of December 31, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K. 22
The Company does not expect that sales revenue and cash flows will be sufficient to support operations and cash requirements until it has fully implemented its product strategy. During the year ended December 31, 2022 the Company used $10,506,575 in cash for operations.
The Company does not expect that sales revenue and cash flows will be sufficient to support operations and cash requirements until it has fully implemented its product strategy. During the year ended December 31, 2023 the Company used $9,536,879 in cash for operations.
Additional projected product revenues are not anticipated to result in a positive cash flow position for the year 2023 overall and, as of December 31, 2022, the Company has working capital of $7,470,521. Although the Company has working capital, additional financing will be required for the Company to reach a level of sufficient sales to achieve profitability.
Additional projected revenues are not anticipated to result in a positive cash flow position for the year 2024 overall and, as of December 31, 2023, the Company has working capital deficit of $4,225,559. As such, additional financing will be required for the Company to reach a level of sufficient sales to achieve profitability.
Any adjustments to fair value are treated as gains and losses in fair values of derivatives and are recorded on the Statement of Operations. Please refer to Note 10 for further discussion on embedded derivatives. Revenue Recognition: Product revenue.
Any adjustments to fair value are treated as gains and losses in fair values of derivatives and are recorded on the Statement of Operations. Revenue Recognition: Product revenue.
Research, development and manufacturing operations costs include costs incurred for product development, pre-production and production activities in our manufacturing facility. Research, development and manufacturing operations costs also include costs related to technology development. Research, development and manufacturing operations costs increased by $1,835,602 or 44%, for the year ended December 31, 2022 when compared to the same period in 2021.
Research, development and manufacturing operations costs include costs incurred for product development, pre-production and production activities in our manufacturing facility. Research, development and manufacturing operations costs also include costs related to technology development. Research, development and manufacturing operations costs decreased by $2,753,638 or 46%, for the year ended December 31, 2023 when compared to the same period in 2022.
Our Net Loss was $19,754,705 for the year ended December 31, 2022, compared to Net Loss of $6,000,003 for the year ended December 31, 2021, an increase of $13,754,702. The increase is due to the reasons described above. Liquidity and Capital Resources The Company has continued limited PV production at its manufacturing facility.
Our Net Loss was $17,069,896 for the year ended December 31, 2023, compared to Net Loss of $19,754,705 for the year ended December 31, 2022, a decrease of $2,684,809. The decrease is due to the reasons described above. Liquidity and Capital Resources The Company has continued limited PV production at its manufacturing facility.
This is partially offset by lower repair and maintenance costs in the current period. Management believes our factory is currently significantly under-utilized, and a substantial increase in revenue would result in marginal increases to direct labor and overhead included in the cost of revenues. Research, development and manufacturing operations.
This is partially offset by increased expenses from our asset acquisition of Flisom's manufacturing equipment and employee contract. Management believes our factory is currently significantly under-utilized, and a substantial increase in revenue would result in marginal increases to indirect labor and overhead included in the cost of revenues. Research, development and manufacturing operations.
Statements of Cash Flows Comparison of the Years Ended December 31, 2022 and 2021 For the year ended December 31, 2022, our cash used in operations was $10,506,575 compared to $9,404,443 for the year ended December 31, 2021, an increase of $1,102,132.
Statements of Cash Flows Comparison of the Years Ended December 31, 2023 and 2022 For the year ended December 31, 2023, our cash used in operations was $9,536,879 compared to $10,506,575 for the year ended December 31, 2022, a decrease of $969,696.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Management is evaluating the impact of this ASU on the Company’s financial statement presentation.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Management adopted ASU 2020-06 on January 1, 2023. Management is evaluating the impact of other new pronouncements issued but not effective as of December 31, 2023.
This change was primarily the result of a decrease purchase of equipment partially offset by a contribution to Ascent Germany. During the year ended December 31, 2022, cash used in operations of $10,506,575 were primarily funded through $18,500,000 in proceeds from issuances of debt and common stock.
This change was primarily the result of the purchase of Flisom's manufacturing equipment in Switzerland. During the year ended December 31, 2023, cash used in operations of $9,536,879 were primarily funded through $11,200,000 in proceeds from issuances of preferred and common stock during 2023 and $13,500,000 in proceeds from the issuance of convertible debt in 2022.
The increase in cost is due primarily to increased operations in the current year as compared to the Company’s restart status in the prior year. Selling, general and administrative. Selling, general and administrative expenses increased by $1,438,580, or 44%, for the year ended December 31, 2022 when compared to the same period in 2021.
Selling, general and administrative expenses increased by $627,961, or 13%, for the year ended December 31, 2023 when compared to the same period in 2022. The increase in costs is due primarily to increased professional services and other administrative expenses.
For the year ended December 31, 2022 we generated $1,222,786 of total revenue, of which, product sales accounted for $694,286 and milestone and engineering revenue accounted for $528,500. As of December 31, 2022, we had an accumulated deficit of approximately $447,537,493.
For the year ended December 31, 2023 we generated $458,260 of total revenue, of which, product sales accounted for $397,886 and milestone and engineering revenue accounted for $60,374. As of December 31, 2023, we had an accumulated deficit of approximately $482,478,436.
Our revenues increased by $615,003, or 101%, for the year ended December 31, 2022 when compared to the same period in 2021. The increase in sales is due primarily to Milestone and engineering revenue from TubeSolar in the current period. Cost of revenues. Cost of revenues is comprised primarily of repair and maintenance, direct labor and overhead expenses.
Total revenues decreased by $764,526, or by 63%, for the year ended December 31, 2023 when compared to the same period in 2022. The decrease in sales is due primarily to Milestone and engineering revenue from TubeSolar in 2022 which was not repeated in the current year.
The increase is primarily the result of scaling up operations during the current year as compared to the Company’s restart status during 2021. For the year ended December 31, 2022, cash used in investing activities was $265,472 compared to cash used in investing activities of $301,522 for the year ended December 31, 2021.
The decrease is primarily the result of the decrease in manufacturing, the redeployment of the Thornton manufacturing facility as a Perovskite research facility, and the restart of limited manufacturing. For the year ended December 31, 2023, cash used in investing activities was $3,877,366 compared to cash used in investing activities of $265,472 for the year ended December 31, 2022.
Our cost of revenues increased by $109,045, or 6% for the year ended December 31, 2022 when compared to the same period in 2021. The increase in cost of revenues is mainly due to the increase in materials and freight, and labor costs as a result of increased production during the current year.
Our cost of revenues decreased by $119,118, or 6% for the year ended December 31, 2023 when compared to the same period in 2022. The decrease in cost of revenues is primarily due to the decrease in manufacturing costs as the Company redeployed it manufacturing facilities to a research facility in March 2023 and restarted limited manufacturing in late 2023.
The increase in costs is due primarily to an increased level of operations in the current period as compared to the Company’s restart status in the prior period. Additionally, the Company incurred a one-time termination expense of approximately $500,000 and $157,000 recognized with the departure of our former CEO and CFO, respectively, in the current period. Share-based compensation.
This increase is partially offset by one-time termination expense of approximately $500,000 and $157,000 recognized with the departure of our former CEO and CFO, respectively, in 2022. Share-based compensation. Share-based compensation expense decreased by $3,235,289 or 59%, for the year ended December 31, 2023 when compared to the same period in 2022.